Forty‐three Key Gene Expressions Involved in the Effect of Indoleamine 2,3‐dioxygenase 1 Expression on Cancer Prognosis May Be a Potential Indoleamine 2,3‐dioxygenase 1 Inhibitor Biomarker
Weirui Li,Leilei Guo,Zikang Xing,Xin Fang,Heng Liang,Shengnan Zhang,Lei Shi,Chunxiang Kuang,Leming Shi,Yuanting Zheng,Yueqing Hu,Qing Yang
DOI: https://doi.org/10.1002/ctm2.330
IF: 8.554
2021-01-01
Clinical and Translational Medicine
Abstract:Indoleamine 2,3-dioxygenase 1 (IDO1) inhibition has been developed as a potential new tool in cancer immunotherapy and some IDO1 inhibitors have been in clinical trials.1 However, the biomarker information of IDO1 inhibitors is very few. Here, we searched for potential IDO1 inhibitors biomarker by identifying molecular characteristic that can predict the effect of IDO1 on cancer prognosis. We evaluated the effect of IDO1 mRNA expression on prognosis in 33 diverse cancer types, identified 43 key genes involved in the effect, and defined the weighted average of all the 43 key gene expressions as 43-gene score to reflect the integrated role of 43 key gene expressions in the relationship between IDO1 expression and cancer prognosis. We mined the potential regulator of 43 key genes and explored its impacts on regulating the expressions of 43 key genes and enhancing the therapeutic efficacy of IDO1 inhibitor (Figure 1). Specifically, we used Kaplan-Meier method and Cox proportional hazards (CoxPH) regression model to compare the overall survival (OS) and progression-free interval (PFI) of patients with high and low IDO1 expressions2, 3 (Table S1) and evaluated the effects of IDO1 expression on prognosis in 33 diverse cancer types from The Cancer Genome Atlas (TCGA) (Figure S1). These types of cancer were then classified into IDO1 protective category, in which IDO1 has beneficial effects on prognosis, IDO1 deleterious category, in which IDO1 has disadvantageous effects on prognosis, and IDO1 neutral category, in which IDO1 has no effects on prognosis (see Table S2 for more details). From the discovery set, which is a random partition of patients of protective and deleterious categories, computational tools such as the detection of differentially expressed genes (DEGs),4 weighted gene co-expression network analysis (WGCNA)5 (Figure 2A; Figures S2-S6), gene set enrichment analysis (GSEA)6 (Figure 2B,C) and protein-protein interaction network (PPIN) analysis7 (Figure 2D) were employed to obtain five candidate gene sets. Totally, 540 candidate genes associated with the effects of IDO1 expression on prognosis were collected and shown in Table S3. Based on a random-forest variable importance measure, these genes were further refined to 43 key genes (Table S4) and 43-gene score. The 43-gene scores were significantly lower in IDO1 deleterious category than that in IDO1 protective category (Figure 2E). The effects of IDO1 on prognosis were more significant in two subgroups separated by the median of 43-gene scores than that in the whole discovery set (Figure 2F). We also got the similar observation in the validation set 1 (Figure 2G). For the patients in the discovery set and the validation set 1, 43-gene score showed superior prediction power, especially over the patient category (Figure 2H). Within our expectation, the performance of 43-gene score was not strong in the validation set 2, in which all the patients are of the IDO1 neutral category (Figure S7). Even so, we observed that some key genes, such as glial fibrillary acidic protein (GFAP) and X-C motif chemokine ligand 1 (XCL1), still performed well in the validation set 2 (Figure 2I). All of these illustrated that 43-gene score is a better biomarker than the patient category regarding the efficacy of IDO1 inhibitors and may also reflect the immune landscape in tumor. We further found that the tumor immune subtype was distributed differently among patients of IDO1 protective, deleterious, and neutral categories (Figure S3). IDO1 had a beneficial effect on prognosis in patients with tumor immune subtype C1 (Wound Healing) or C2 (IFN-gamma Dominant), a disadvantageous effect in patients with C3 (Inflammatory) or C5 (Immunologically Quiet) (Figure S4). We identified four co-expression modules that were associated with tumor immune subtype and patient category based on their respective correlations with module eigengenes of modules (Figure S5). The correlations between gene significance (GS) and module membership (MM) in the four modules were illustrated in Figure S6, which confirmed that the larger the MM of a gene was, the stronger the correlation between the gene and immune subtype or patient category was. Tumors with C1 or C2 have the highest proportion of tumor infiltrating lymphocytes and tumors with C3 or C5 have the opposite.8 It can be concluded that IDO1 inhibitors are applicable for the patients with C3 or C5 because IDO1 has a disadvantageous effect on their prognoses. We also found that tumor immune subtype's distributions were significantly different in patients with high and low GFAP or XCL1 expressions and in patients with high and low 43-gene scores (Figure S8). These suggest that GFAP and XCL1 may be the more important ones among the 43 key genes. We sought to find the potential regulator of the expressions of 43 key genes using the Genomics of Drug Sensitivity in Cancer database. As IDO1 high expression correlates to good prognosis in patients with high 43-gene scores, a hierarchical logistic regression model was employed to fit the efficacy measures of 251 drugs across 983 human cell lines, and further to identify drugs more sensitive to that cell lines with higher 43-gene scores. As a result, EGFR inhibitor gefitinib was mined (Figure 3A-E). Using LLC cells and LLC tumor-bearing mouse model,9 the effect of gefitinib in regulating expressions of key genes (Figure 3F,I) and enhancing the therapeutic efficacy of IDO1 inhibitor (INCB024360, L-1-MT, and RY103) were explored (Figures 3G,H,J), which supports the possibility of key gene expressions as a biomarker for IDO1 inhibitors. To exhibit the stability of our procedure for obtaining key genes, we randomly partitioned the patients in either the IDO1 protective or deleterious category into a new discovery set and a new validation set 1, and then repeated the same steps and finally got the similar results (see details in Tables S5 and S6 and Figure S9. Our study provides a possible strategy for the screening of IDO1 inhibitor biomarker and suggests a new therapeutic strategy to enhance the therapeutic efficacy of IDO1 inhibitors. Qing Yang, Yuanting Zheng, Yueqing Hu, and Weirui Li conceived and designed the study. Weirui Li processed the data and led the bioinformatics analysis. Weirui Li, Leilei Guo, Zikang Xing, Xin Fang, Heng liang, Shengnan Zhang, and Lei Shi performed the qPCR, HPLC analysis, and the animal experiments. Chunxiang Kuang designed and synthesized the IDO1 inhibitor RY103. Qing Yang, Yueqing Hu, and Weirui Li wrote the manuscript. Qing Yang, Yuanting Zheng, Yueqing Hu, and Leming Shi supervised the project. All the authors contributed to the critical revision of the manuscript and approved the final version. This work was supported by the Key Biomedical Program of Shanghai (NO. 18431902600 &17431902200) and the National Natural Science Foundation of China (NO. 11971117). The datasets used or analyzed in this study are available from the corresponding author on reasonable request. All the authors consent for publication. The authors declare no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.